In vitro antitumor lymphocyte generation using dendritic cells and innate immunity mechanisms as tumor cell treatments

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2385-2392

  Gervais, Alban ^a   Toutirais, Olivier ^a   Bouet Toussaint, Françoise ^a,b   De La Pintiere, Cecile Thomas ^b   Genetet, Noelle ^a,b   Catros Quemener, Veronique ^a,b  

^a Inst de Med Légale   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Dendritic cell; Immunotherapy; Innate immunity; Lymphocyte; Tumor associated antigen

Indexed keywords

GAMMA INTERFERON; HYPOCHLORITE SODIUM; IMMUNOGLOBULIN G; MELAN A; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; INNATE IMMUNITY; MELANOMA CELL; NORMAL HUMAN; OPSONIZATION; PRIORITY JOURNAL; TUMOR CELL;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DENDRITIC CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; K562 CELLS; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547737070     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
2. Zhang X, Gordon JR and Xiang J: Advances in dendritic cell-based vaccine of cancer. Cancer Biother Radiopharm 17: 601-619, 2002.
3. Armstrong AC, Eaton D and Ewing JC: Cellular vaccine therapy for cancer. Expert Rev Vaccines 1: 303-316, 2002.
4. Moretta A: Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2: 957-964, 2002.
5. Gervais A, Bouet-Toussaint F, Toutirais O, De La Pintiere CT, Genetet N and Catros-Quemener V: Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells. Anticancer Res 25: 2177-2185, 2005.
6. Chaput N, Taieb J, Schartz NE, Andre F, Angevin E and Zitvogel L: Exosome-based immunotherapy. Cancer Immunol Immunother 53: 234-239, 2004.
7. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P and Amigorena S: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425: 397-402, 2003.
8. Albert ML, Sauter B and Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89, 1998.
9. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D and Desjardins M: Phagosomes are competent organelles for antigen cross-presentation. Nature 425: 402-406, 2003.
10. Diefenbach A and Raulet DH: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 188: 9-21, 2002.
11. Werling D and Jungi TW: TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 91: 1-12, 2003.
12. Reeves EP, Nagl M, Godovac-Zimmermann J and Segal AW: Reassessment of the microbicidal activity of reactive oxygen species and hypochlorous acid with reference to the phagocytic vacuole of the neutrophil granulocyte. J Med Microbiol 52: 643-651, 2003.
13. Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL and Ganesan TS: Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 9: 84-92, 2003.
14. Dutta T, Spence A and Lampson LA: Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J Neurooncol 64: 31-44, 2003.
15. Akiyama K, Ebihara S, Yada A, Matsumura K, Aiba S, Nukiwa T and Takai T: Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 170: 1641-1648, 2003.
16. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K and Gregoire M: Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 59: 3329-3332, 1999.
17. Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118, 1994.
18. Jonuleit H, Schmitt E, Steinbrink K and Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22: 394-400, 2001.
19. Pittet MJ, Speiser DE, Valmori D, Rimoldi D, Lienard D, Lejeune F, Cerottini JC and Romero P: Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol 1: 1235-1247, 2001.
20. Granucci F, Zanoni I, Feau S and Ricciardi-Castagnoli P: Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. Embo J 22: 2546-2551, 2003.
21. Steinman RM: Some interfaces of dendritic cell biology. APMIS 111: 675-697, 2003.
22. Borg C, Taieb J, Terme M, Maruyama K, Flament C, Angevin E and Zitvogel L: NK cell-based immunotherapy: new prospects and involvement of dendritic cells. Bull Cancer 90: 699-705, 2003.
23. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H and Whiteside TL: Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60: 3542-3549, 2000.
24. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S and Eigler A: Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61: 6445-6450, 2001.
25. Kass R, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S and Santin AD: Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat 80: 275-285, 2003.
26. Diefenbach A, Hsia JK, Hsiung MY and Raulet DH: A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 33: 381-391, 2003.
27. Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A and Mellstedt H: Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 17: 894-899, 2003.
28. Latouche JB and Sadelain M: Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 18: 405-409, 2000.
29. Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A and Mackensen A: Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res 6: 1997-2005, 2000.
30. Albert ML: Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 4: 223-231, 2004.
31. Hall HT, Petrovic J and Hoglund P: Reduced antigen concentration and costimulatory blockade increase IFN-gamma secretion in naive CD8+ T cells. Eur J Immunol 34: 3091-3101, 2004.
32. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE and Shu S: CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 20: 17-56, 2000.